Zaid Rana
Gastroenterology · Miami, FLNPI 1558801159
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,033 of the $4,673 with a category attached, or 64.9%. Boston Scientific accounts for 65.6% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2022 at $2,145 and has fallen 58.2% since, to $897 in 2025.
Across 69 payments — averaging $67.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$3K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$260
- Redhill Biopharma Inc.$201
- Madrigal Pharmaceuticals$179
- Fujifilm Healthcare Americas Corporation$140
- Bristol Myers Squibb$135
- plus $694 from 11 others
Across 993 payments — averaging $5421.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$3.1M
- Teva Pharmaceuticals USA, Inc.$1.1M
- Takeda Pharmaceuticals U.S.A., Inc.$454K
- Incyte Corporation$424K
- Chiesi USA, Inc.$168K
- Boehringer Ingelheim International GmbH$149K
- plus $18K from 1 others
What the payments were for
- Travel & lodging$1,64035%
- Food & beverage$3,03365%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 22 | $3,065 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $260 |
| Redhill Biopharma Inc. | 10 | $201 |
| Madrigal Pharmaceuticals | 6 | $179 |
| Fujifilm Healthcare Americas Corporation | 2 | $140 |
| Bristol Myers Squibb | 1 | $135 |
| Janssen Scientific Affairs, LLC | 1 | $122 |
| Esperion Therapeutics, Inc. | 1 | $119 |
| Gilead | 1 | $109 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $84 |
| NS Pharma, Inc. | 1 | $53 |
| Chiesi USA, Inc. | 1 | $50 |
| Merck | 3 | $44 |
| Intercept Pharmaceuticals, Inc. | 2 | $41 |
| AbbVie | 2 | $39 |
| Johnson & Johnson | 1 | $17 |
| EMD Serono, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EXALT Model D$1,835
- OverStitch NXT Endoscopic Suturing System$175
- AXIOS$149
- Revlimid$135
- STELARA$122
- NEXLIZET$119
- NEXLETOL$119
- Truvada$109
- OverStitch Endoscopic Suturing System$107
How this compares
$4,673 in reported general payments places this provider in the 60th percentile of 1,388 gastroenterology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 17 | $1,216 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Miami
- Lukasz KwapiszMiami$1.2M
- Joanna LopezMiami$670K
- Jerry MartelMiami$511K
- Andres GelrudMiami$208K
- Maria HernandezMiami$197K
- George SanchezMiami$117K
- Jodie BarkinMiami$101K
- Javier ParraMiami$68K
- Samuel GidayOrlando$2M
- Jennifer Seminerio-DiehlOrlando$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.